Literature DB >> 15083265

Effects of a single dose of 3,4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naive rats and rats previously exposed to MDMA.

Brigitta Balogh1, Eszter Molnar, Rita Jakus, Linda Quate, Henry J Olverman, Paul A T Kelly, Sandor Kantor, Gyorgy Bagdy.   

Abstract

RATIONALE: Despite the well documented neurochemical actions of 3,4-methylenedioxymethamphetamine (MDMA), acute effects in rats previously exposed to the drug have not been extensively explored.
OBJECTIVE: To examine motor activity and vigilance effects of MDMA in drug-naive rats and in rats exposed to the drug 3 weeks earlier.
METHODS: MDMA (15 mg/kg, i.p.) was administered to Dark Agouti rats. Motor activity, wakefulness, light slow wave sleep (SWS-1), deep slow wave sleep (SWS-2) and paradoxical sleep (PS), sleep and PS latencies were measured. Acrophases and amplitudes of the 24 h cycles were calculated by cosinor analysis. In parallel groups, local cerebral glucose utilization (lCMRglu) and (3H)-paroxetine binding were measured in motor areas of the brain.
RESULTS: In drug-naive rats MDMA caused marked increases in motor activity and wakefulness for at least 5-6 h. Circadian patterns of motor activity and sleep/vigilance parameters were altered up to 5 days after treatment. Despite most parameters tending to return to normal, there were still significant effects of MDMA on motor activity, wakefulness, and SWS-2 28 days later. Acute MDMA administration caused significant increases in lCMRglu, but after 3 weeks lCMRglu was decreased in the same brain areas. No significant change in [3H]paroxetine binding was observed in motor areas, although significant reductions were seen elsewhere (neocortex -81%). In rats exposed to MDMA 3 weeks earlier, most acute effects induced by MDMA administration were similar to those in drug-naive rats, but shorter duration of the acute effects were found in motor activity and vigilance.
CONCLUSIONS: Our findings provide evidence that MDMA use can lead to long-term changes in regulation of circadian rhythms, motor activity and sleep generation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15083265     DOI: 10.1007/s00213-004-1787-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  83 in total

1.  Studies on the neuroprotective effect of the enantiomers of AR-A008055, a compound structurally related to clomethiazole, on MDMA ("ecstasy")-induced neurodegeneration in rat brain.

Authors:  M I Colado; E O'Shea; B Esteban; A R Green
Journal:  Psychopharmacology (Berl)       Date:  2001-08       Impact factor: 4.530

2.  3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose.

Authors:  B Esteban; E O'Shea; J Camarero; V Sanchez; A R Green; M I Colado
Journal:  Psychopharmacology (Berl)       Date:  2001-03       Impact factor: 4.530

3.  Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue.

Authors:  C J Schmidt; L Wu; W Lovenberg
Journal:  Eur J Pharmacol       Date:  1986-05-13       Impact factor: 4.432

4.  MDMA alters the response of the circadian clock to a photic and non-photic stimulus.

Authors:  Suzanne Colbron; Mark Jones; Stephany M Biello
Journal:  Brain Res       Date:  2002-11-22       Impact factor: 3.252

Review 5.  Circadian rhythm sleep disorders: pathophysiology and treatment.

Authors:  G S Richardson; H V Malin
Journal:  J Clin Neurophysiol       Date:  1996-01       Impact factor: 2.177

Review 6.  Human research on MDMA (3,4-methylene- dioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change.

Authors:  A C Parrott
Journal:  Neuropsychobiology       Date:  2000       Impact factor: 2.328

Review 7.  (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals.

Authors:  G A Ricaurte; J Yuan; U D McCann
Journal:  Neuropsychobiology       Date:  2000       Impact factor: 2.328

8.  Effects of zimeldine, a selective 5-HT reuptake inhibitor, combined with ritanserin, a selective 5-HT2 antagonist, on waking and sleep stages in rats.

Authors:  B Bjorvatn; R Ursin
Journal:  Behav Brain Res       Date:  1990-11-30       Impact factor: 3.332

9.  Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain.

Authors:  D L Commins; G Vosmer; R M Virus; W L Woolverton; C R Schuster; L S Seiden
Journal:  J Pharmacol Exp Ther       Date:  1987-04       Impact factor: 4.030

10.  Autoradiographic localization of 3H-paroxetine-labeled serotonin uptake sites in rat brain.

Authors:  E B De Souza; B L Kuyatt
Journal:  Synapse       Date:  1987       Impact factor: 2.562

View more
  16 in total

1.  Prior MDMA (Ecstasy) use is associated with increased basal ganglia-thalamocortical circuit activation during motor task performance in humans: an fMRI study.

Authors:  John Karageorgiou; Mary S Dietrich; Evonne J Charboneau; Neil D Woodward; Jennifer U Blackford; Ronald M Salomon; Ronald L Cowan
Journal:  Neuroimage       Date:  2009-03-02       Impact factor: 6.556

2.  High-dose MDMA does not result in long-term changes in impulsivity in the rat.

Authors:  Kathryn S Saadat; J Martin Elliott; A Richard Green; Paula M Moran
Journal:  Psychopharmacology (Berl)       Date:  2006-08-09       Impact factor: 4.530

3.  Ultrastructural characterization of tryptophan hydroxylase 2-specific cortical serotonergic fibers and dorsal raphe neuronal cell bodies after MDMA treatment in rat.

Authors:  Csaba Adori; Péter Low; Rómeó D Andó; Lise Gutknecht; Dorottya Pap; Ferencné Truszka; József Takács; Gábor G Kovács; Klaus-Peter Lesch; György Bagdy
Journal:  Psychopharmacology (Berl)       Date:  2010-10-30       Impact factor: 4.530

4.  MDMA induces Per1, Per2 and c-fos gene expression in rat suprachiasmatic nuclei.

Authors:  Rowan P Ogeil; David J Kennaway; Mark D Salkeld; Shantha M W Rajaratnam; Jillian H Broadbear
Journal:  Psychopharmacology (Berl)       Date:  2011-10-26       Impact factor: 4.530

5.  MDMA (Ecstasy) association with impaired fMRI BOLD thalamic coherence and functional connectivity.

Authors:  Ronald M Salomon; John Karageorgiou; Mary S Dietrich; Jessica Y McLellan; Evonne J Charboneau; Jennifer U Blackford; Ronald L Cowan
Journal:  Drug Alcohol Depend       Date:  2011-07-31       Impact factor: 4.492

6.  Fentanyl, but not haloperidol, entrains persisting circadian activity episodes when administered at 24- and 31-h intervals.

Authors:  Andrea G Gillman; Joseph K Leffel; Ann E K Kosobud; William Timberlake
Journal:  Behav Brain Res       Date:  2009-07-10       Impact factor: 3.332

7.  Activation of 5-HT3 receptors leads to altered responses 6 months after MDMA treatment.

Authors:  Norbert Gyongyosi; Brigitta Balogh; Zita Katai; Eszter Molnar; Rudolf Laufer; Kornelia Tekes; Gyorgy Bagdy
Journal:  J Neural Transm (Vienna)       Date:  2010-01-06       Impact factor: 3.575

8.  Pre- and post-nicotine circadian activity rhythms can be differentiated by a paired environmental cue.

Authors:  Andrea G Gillman; Ann E K Kosobud; William Timberlake
Journal:  Physiol Behav       Date:  2007-09-26

9.  The recreational drug ecstasy disrupts the hypothalamic-pituitary-gonadal reproductive axis in adult male rats.

Authors:  Sarah M Dickerson; Deena M Walker; Maria E Reveron; Christine L Duvauchelle; Andrea C Gore
Journal:  Neuroendocrinology       Date:  2008-02-29       Impact factor: 4.914

10.  Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) and R(-) MDMA on actigraphy-based daytime activity and sleep parameters in rhesus monkeys.

Authors:  Laís F Berro; Hannah Shields; Melis Odabas-Geldiay; Barbara O Rothbaum; Monica L Andersen; Leonard L Howell
Journal:  Exp Clin Psychopharmacol       Date:  2018-06-25       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.